ArticleTargeted oncology2026

Evaluation of Olaparib Efficacy Following CDK4/6 Inhibitor Therapy in BRCA-Mutated, Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: A Turkish Oncology Group (TOG) Study.

Zeynep Sıla Gökdere et al.PubMed ↗Publisher ↗

No numbers read from the abstract.